Soleno Therapeutics Inc. (SLNO)
73.74
5.48 (8.03%)
At close: Apr 02, 2025, 3:59 PM
71.96
-2.41%
After-hours: Apr 02, 2025, 07:49 PM EDT
Soleno Therapeutics Income Statement
Financials in USD. Fiscal year
is
January - December.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -1.55B | 1.45M | 387.56K | n/a | 3M | n/a |
| Cost of Revenue | n/a | 1.96M | 2.21M | 2.21M | 2.19M | 2.3M | 1.92M | 1.61M | 1.51M | 352.68K | n/a | n/a | n/a |
| Gross Profit | n/a | -1.96M | -2.21M | -2.21M | -2.19M | -2.3M | -1.92M | -1.55B | -58.52K | 34.87K | n/a | 3M | n/a |
| Operating Income | n/a | -41.38M | -24.4M | -31.53M | -36.29M | -23.49M | -14.3M | -12.17M | -13.61M | -12.16M | -5.16M | -846.78K | -3.6M |
| Interest Income | n/a | 2.58M | 300K | 110K | 13K | 154K | n/a | n/a | n/a | n/a | 1.08K | 1.77K | 3.1K |
| Pretax Income | -175.85M | -38.99M | -24.07M | -30.91M | -24.64M | -30.77M | -11.84M | -13.72M | -12.04M | -15.91M | -13.87M | -3.71M | -6.48M |
| Net Income | -175.85M | -38.99M | -20.32M | -29.56M | -15.38M | -35.91M | -13.34M | -15.67M | -12.07M | -15.91M | -13.87M | -3.71M | -6.48M |
| Selling & General & Admin | 105.86M | 13.48M | 9.84M | 10.81M | 8.76M | 6.93M | 6.56M | 6.61M | 8.37M | 7.88M | 2.92M | 1.47M | 1.13M |
| Research & Development | 78.57M | 25.19M | 15.27M | 21.45M | 23.19M | 16.27M | 7.18M | 3.07M | 5.18M | 4.54M | 2.24M | 2.38M | 2.47M |
| Other Expenses | 3.24M | 2.71M | n/a | n/a | 4.34M | 289K | 6K | -585.95K | -100.52K | -183.56K | -4.59M | -1.97K | -22.41K |
| Operating Expenses | 187.67M | 41.38M | 25.11M | 32.26M | 31.95M | 23.2M | 13.73M | 9.68M | 13.55M | 12.19M | 5.16M | 3.85M | 3.6M |
| Interest Expense | -231K | n/a | n/a | n/a | n/a | n/a | 62K | n/a | n/a | n/a | 4.13M | 2.86M | 2.87M |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 25.73K | 1.63M | 1.74M | 252.36K | n/a | n/a |
| Cost & Expenses | n/a | 41.38M | 25.11M | 32.26M | 31.95M | 23.2M | 13.73M | 9.68M | 15.06M | 12.55M | 5.16M | 3.85M | 3.6M |
| Income Tax | n/a | n/a | -3.75M | -1.35M | -9.26M | 5.14M | 2.52M | -1.65M | 21.7K | -183.56K | -455.08K | 2.86M | 2.84M |
| Shares Outstanding (Basic) | 40.18M | 16.49M | 8.4M | 5.32M | 4.17M | 2.28M | 1.4M | 598.52K | 206.77K | 125.68K | 16.93K | 18.68K | 18.68K |
| Shares Outstanding (Diluted) | 40.18M | 16.49M | 8.4M | 5.32M | 4.17M | 2.28M | 1.4M | 598.52K | 206.77K | 125.68K | 16.93K | 18.68K | 18.68K |
| EPS (Basic) | -4.38 | -2.36 | -2.42 | -5.56 | -3.68 | -15.78 | -9.54 | -26.18 | -58.35 | -126.58 | -819.38 | -198.45 | -346.98 |
| EPS (Diluted) | -4.38 | -2.36 | -2.42 | -5.56 | -3.68 | -15.78 | -9.54 | -26.18 | -58.35 | -126.58 | -819.38 | -198.45 | -346.98 |
| EBITDA | n/a | -37.03M | -21.86M | -28.7M | -30M | -28.48M | -9.92M | -8.07M | -6.72M | -15.8M | -5.13M | -804.86K | -3.57M |
| EBIT | n/a | -38.99M | -24.07M | -32.26M | -31.95M | -23.2M | -13.73M | -13.44M | -6.74M | -12.16M | -9.74M | -846.98K | -3.62M |
| Depreciation & Amortization | n/a | 1.96M | 2.21M | 2.21M | 2.19M | 2.3M | 1.92M | 1.61M | 19.7K | 108.23K | 28.52K | 42.11K | 43.79K |